Research Information Only — Educational content, not medical advice. Both are prescription medications; the choice belongs to your physician.
PeptideReport.ai
Compare › Semaglutide vs Tirzepatide

Head-to-Head · Weight Loss Hub

Semaglutide vs Tirzepatide

The two most-searched weight-loss medications, side by side. One works on a single gut-hormone pathway; the other works on two, and out-lost the first in a direct trial. But "more powerful" and "right for you" aren't the same question — and confusing them is how people end up on the wrong drug for their goal.

GLP-1 vs GLP-1+GIPSingle vs Dual Pathway~15% vs ~20%FDA-Approved Brands

The Short Answer

One pathway versus two

The whole difference starts with how many gut-hormone systems each drug switches on. Semaglutide activates the GLP-1 receptor — one pathway. Tirzepatide activates GLP-1 and GIP — two. That extra pathway is why tirzepatide produced greater average weight loss in trials and beat semaglutide head-to-head. But semaglutide has the longer real-world track record and remains a first choice in several diabetes contexts. Stronger on average isn't the same as right for one person.

Single Agonist

Semaglutide

  • Activates GLP-1 (one pathway)
  • ~15% average weight loss in trials
  • Longest track record of the two
  • Established default in many diabetes cases
  • FDA-approved brands for weight & T2D
vs
Dual Agonist

Tirzepatide

  • Activates GLP-1 + GIP (two pathways)
  • ~20–22% average weight loss in trials
  • Beat semaglutide in a head-to-head study
  • Generally the stronger weight-loss option
  • FDA-approved brands for weight & T2D

Side by Side

The full comparison

MechanismSemaglutide: GLP-1 mono-agonistTirzepatide: GLP-1 + GIP dual agonist
Avg. trial weight loss~15%~20–22% (higher head-to-head)
DosingOnce weekly, titratedOnce weekly, titrated
Side effectsGI: nausea, fullness, constipationSame GI profile; can be stronger at higher doses
Track recordLonger, more real-world dataNewer, powerful results
Diabetes roleEstablished; often the defaultAlso approved; strong metabolic effect
StatusFDA-approved (brand names)FDA-approved (brand names)

Which One Fits

Goal and diagnosis decide — not potency

Semaglutide leans right if…

  • Type-2 diabetes is confirmed (often the default)
  • You want the longest track record
  • A more moderate goal fits your situation
  • Tolerance or availability favors it

Tirzepatide leans right if…

  • The weight-loss goal is larger
  • You want the greater average effect
  • The dual pathway suits your metabolic picture
  • You can tolerate a stronger titration
Same rules for bothBoth share the same GI side effects and the same fixes — slow titration, smaller lower-fat meals — and both carry the same hard stops (pancreatitis history rules out the class; medullary thyroid carcinoma / MEN2 is a contraindication). And with either, the shot is the assist, not the plan. Why you can't just coast on the shot →

Common Questions

Semaglutide vs tirzepatide, answered

What's the core difference?
Pathway count. Semaglutide hits one gut-hormone receptor (GLP-1); tirzepatide hits two (GLP-1 + GIP), which drove greater average weight loss and a head-to-head win. Both are FDA-approved brands. Tirzepatide is generally stronger for weight; semaglutide has the longer record.
Which loses more weight?
Tirzepatide on average — roughly 20–22% vs ~15% in pivotal trials, and it beat semaglutide directly. But average isn't individual, and the stronger drug isn't automatically the right one for your goal and tolerance.
Are the side effects different?
Same profile — GI effects from slowed gastric emptying — managed the same way. Because tirzepatide is more potent, effects can be more pronounced at higher doses, which is why titration matters.
How do I choose?
By goal and diagnosis, with your physician. A larger goal favors tirzepatide's dual action; confirmed diabetes often leads with semaglutide. Tolerance, cost, and availability all factor in — it's a clinical decision, not a potency contest.

Brand Names

You may know these by their brand namesSemaglutide is sold as Ozempic and Wegovy (and oral Rybelsus); tirzepatide as Mounjaro and Zepbound.

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on metabolic medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked. No products are sold on this site.

Full Disclaimer

Semaglutide and tirzepatide are prescription medications, FDA-approved under specific brand names for weight management and type-2 diabetes with specific indications. This page is for educational purposes only and does not constitute medical advice; the choice between them, dosing, and monitoring must be made by a licensed physician who can evaluate your history, labs, and goals. Both carry contraindications including a personal or family history of medullary thyroid carcinoma or MEN2, and a history of pancreatitis. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.